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Abstract: Type 2 diabetes is a metabolic disease categorized primarily by reduced insulin 
sensitivity, B-cell dysfunction, and elevated hepatic glucose production. Treatments reducing 
hyperglycemia and the secondary complications that result from these dysfunctions are being 
sought after. Two distinct pathways encourage glucose transport activity in skeletal muscle, ie, 
the contraction-stimulated pathway reliant on Ca2/5a-monophosphate-activated protein kinase 
(AMPK)-dependent mechanisms and an insulin-dependent pathway activated via upregulation 
of serine/threonine protein kinase Akt/PKB. Metformin is an established treatment for type 2 
diabetes due to its ability to increase peripheral glucose uptake while reducing hepatic glucose 
production in an AMPK-dependent manner. Peripheral insulin action is reduced in type 2 diabet-
ics whereas AMPK signaling remains largely intact. This paper firstly reviews AMPK and its 
role in glucose uptake and then focuses on a novel mechanism known to operate via an insulin-
dependent pathway. Inositol hexakisphosphate (IP6) kinase 1 (IP6K1) produces a pyrophosphate 
group at the position of IP6 to generate a further inositol pyrophosphate, ie, diphosphoinositol 
pentakisphosphate (IP7). IP7 binds with Akt/PKB at its pleckstrin homology domain, prevent-
ing interaction with phosphatidylinositol 3,4,5-trisphosphate, and therefore reducing Akt/PKB 
membrane translocation and insulin-stimulated glucose uptake. Novel evidence suggesting a 
reduction in IP7 production via IP6K1 inhibition represents an exciting therapeutic avenue in 
the treatment of insulin resistance. Metformin-induced activation of AMPK is a key current 
intervention in the management of type 2 diabetes. However, this treatment does not seem to 
improve peripheral insulin resistance. In light of this evidence, we suggest that inhibition of 
IP6K1 may increase insulin sensitivity and provide a novel research direction in the treatment 
of insulin resistance.
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Metabolic dysfunction in type 2 diabetes
Type 2 diabetes is a multifactorial metabolic disease characterized by defects in B-cell 
function and insulin action and increased hepatic glucose production.1 Metabolic 
dysfunction in type 2 diabetes is also the product of reduced glucose effectiveness or 
the ability of glucose to transport itself by a mass action effect.2 Central to this meta-
bolic condition is altered glucose and lipid metabolism resulting from the combined 
effects of insulin resistance in skeletal muscle, hepatic, renal, and adipose tissue. The 
resulting hyperglycemia is the primary cause of the secondary complications associ-
ated with type 2 diabetes. Thus, treatments that target glucose uptake while reducing 
gluconeogenesis are key in the management of type 2 diabetes.
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Faced with an increased prevalence, which is predicted 
to reach 6.1% of the world’s population by 2025,1 advances 
in the treatment of type 2 diabetes are clearly being sought 
after. There are three main approaches to treatment of diabe-
tes, ie, lifestyle modifications requiring patient-led metabolic 
responsibility, gastric bypass surgery, and pharmaceutical 
interventions. A current and effective target for the phar-
maceutical approach to treatment of type 2 diabetes centers 
around upregulation of the metabolic master switch, ie, 
5a-monophosphate-activated protein kinase (AMPK),3 with 
the use of metformin.
AMPK: a current target in 
management of type 2 diabetes
AMPK is a key regulatory protein ubiquitously expressed 
in cells throughout the human body. In mammalian tissues, 
AMPK is a heterotrimer consisting of a catalytic A subunit 
with two further regulatory subunits, B and G. Each of these 
subunits has two or more isoforms.4,5 The G subunit consists 
of 4-cystathionine-b-synthase domains, which are required 
for binding of adenosine triphosphate (ATP) or adenosine 
monophosphate (AMP). The binding of two AMPs to the 
G subunit leads to conformational changes in the complex 
that result in activation of AMPK through exposure and 
phosphorylation of the Thr172 binding site on the catalytic 
A subunit.6,7 Binding of ATP to the G subunit operates in an 
opposing manner by decreasing AMPK activity, while the 
binding of adenosine diphosphate (ADP) to the regulatory G 
subunit protects AMPK against dephosphorylation.8
A working hypothesis is that upon stimulation, AMPK 
mediates contraction-stimulated GLUT-4 translocation and 
glucose uptake in skeletal muscle via phosphorylation of the 
Rab guanosine triphosphatase (GTPase)-activating protein 
(GAP), AS160, in a manner similar to insulin.9–11 AS160 is 
a proposed downstream target of AMPK and it is suggested 
that phosphorylation of AS160 by AMPK results in decreased 
Rab-GTPase activity, leading to an increase in GTP loading 
on intracellular GLUT-4 storage sites, promoting GLUT-4 
translocation and cell membrane fusion while stimulating 
glucose uptake in adipocytes and skeletal muscle.12–14
Using an in vivo electroporation/gene delivery technique 
that prevents phosphorylation on four regulatory phospho-Akt 
substrate sites on AS160, Kramer et al9 demonstrated that both 
insulin-stimulated and contraction-stimulated glucose trans-
port was impaired in skeletal muscle (tibialis anterior). In the 
same study, overexpression of mutant AS160 with abolished 
Rab-GAP activity showed normal elevations in contraction-
stimulated glucose uptake.9 Furthermore, transgenic mouse 
models lacking AMPKA2 activity in muscle show complete 
inhibition of AS160 phosphorylation and glucose transport 
on stimulation with the AMPK activator, 5-aminoimidazole-
4-carboxamide ribonucleoside. Taken together, these data 
suggest a prominent role of both AMPK and AS160 in glucose 
transport, uptake, and utilization.15
Metformin is extensively used in the treatment and man-
agement of type 2 diabetes. Metformin improves glycemic 
control primarily via suppression of hepatic glucose produc-
tion, and to a lesser extent, but still metabolically important, 
increased peripheral glucose uptake.16 This pharmaceutical 
agent activates hepatocyte-specific AMPK, resulting in 
reduced acetyl-CoA carboxylase activity, increased fatty acid 
oxidation, and suppression of lipogenic enzyme expression.16 
However, recent work suggests that inhibition of gluconeogen-
esis by metformin acts independently of the AMPK pathway 
because hepatic glucose production remains blunted in AMPK-
depleted hepatocytes despite treatment with metformin.17
Metformin is also known to activate AMPK and stimulate 
glucose uptake in isolated rodent skeletal muscle, presum-
ably via the ability of metformin to increase the intracellular 
AMP/ATP ratio.18 In addition, administration of metformin is 
known to increase AMPK activity in human skeletal muscle, 
promote GLUT-4 membrane translocation, and stimulate 
insulin-independent glucose uptake,18 in a manner similar to 
muscle contraction. Although inhibition of hepatic glucose 
production by metformin is considered to be the primary 
mechanism by which AMPK lowers hyperglycemia, its 
ability to increase glucose uptake in peripheral tissue is no 
less important. This action is of particular relevance given 
that peripheral insulin resistance is considered to occur prior 
to hepatic insulin resistance.19 However, it has been noted 
in more recent work using a high-fat mouse model that insu-
lin resistance in the liver precedes reduced insulin action in 
skeletal muscle.20 Recent work carried out in type 2 diabetic 
humans found that administration of metformin 2,550 mg/day 
for 3–4 months increased glucose disposal but did not alter 
insulin receptor substrate-1, class IA phosphatidylinositol-3 
(PI3) kinase, or Akt/protein kinase B (PKB) activity in 
skeletal muscle.21 These results suggest that metformin can 
stimulate glucose transport activity in type 2 diabetics, but 
does so via a mechanism that is independent of the traditional 
insulin signaling pathway in skeletal muscle.
Pathways in type 2 diabetes 
stimulated by insulin or contraction
When forming an understanding of the progression of this dis-
ease, it is important to recognize two points. First, peripheral 
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Figure 1 Insulin and contraction signaling pathways during GLUT-4 recruitment and translocation.
Note: Data from Sakamoto et al.14
Abbreviations: IRS, insulin receptor substrate; PI3-K, class IA phosphatidylinositol 3-kinase; PIP2, phosphatidylinositol (4,5)-bisphosphate; PIP3, phosphatidylinositol 
3,4,5-trisphosphate; PDK1, phosphoinositide-dependent protein kinase-1; Akt, serine/threonine protein kinase; AS160, 160 kDa Akt substrate; GLUT-4, glucose transporter 4; 
GSV, GLUT-4 storage vesicle; Rab-GAP, Rab-GTPase-activating protein; Rab-GDP, guanosine-50-diphosphate-loaded Rab; Rab-GTP, guanosine-50-triphosphate-loaded 
Rab; CaMKK, Ca2/calmodulin-dependent protein kinase kinase; LKB1, Serine/threonine kinase 11; STRAD, putative kinase; MO25, mouse protein 25/scaffold protein; 
AMPK, 5a-monophosphate-activated protein kinase; Thr172, phosphorylated AMPKA at threonine 172; AMP, adenosine monophosphate; ATP, adenosine triphosphate; P, 
phosphorylated site.
glucose uptake into skeletal muscle (the main disposal site 
for glucose) can be promoted via two distinct pathways, ie, 
insulin-dependent mechanisms resulting in recruitment and 
activation of Akt/PKB and contraction-mediated stimulation22 
or hypoxia-mediated stimulation23 of AMPK (Figure 1). It 
has been consistently shown that PI3 kinase is necessary for 
insulin-stimulated but not for contraction-stimulated glucose 
uptake,24–27 while Akt2 knockout mice demonstrate normal 
basal and contraction-stimulated glucose uptake.28 Indeed, 
glucose transport is additive when either hypoxia or contrac-
tile activity are coupled with insulin, whereas hypoxia and 
contractile activity are not.29,30 In support of this is the obser-
vation that wortmannin, a selective inhibitor of PI3 kinase, 
completely blocks insulin-stimulated glucose transport but 
has no effect on contraction-mediated or hypoxia-mediated 
2-deoxy-D-glucose uptake in rat skeletal muscle.25
Thus, insulin-stimulated glucose transport is thought 
to occur independently of AMPK activity,31,32 and when 
defects in the Akt/PKB pathway occur, the likely outcome 
is peripheral insulin resistance.33 In addition, it is worth not-
ing that Akt/PKB and target proteins sitting upstream and 
downstream thereof are defective in type 2 diabetes whereas 
AMPK activation remains largely intact.23,34 This latter point is 
important because peripheral insulin resistance is a catalyst for 
B-cell dysfunction, increased hepatic glucose production, and 
progression of the disease,35 so any intervention that improves 
peripheral insulin resistance may conceivably reverse B-cell 
function and reduce hepatic glucose production.
Hypoxia and contractile activity are known stimulators 
of AMPK, and upon activation, AMPK is widely accepted to 
increase glucose transport activity and GLUT translocation via 
an insulin-independent mechanism. Azevedo et al30 demon-
strated that insulin stimulation of 2-deoxyglucose transport is 
impaired in insulin-resistant tissue. These investigators further 
demonstrated no differences in hypoxia-stimulated glucose 
transport rates between lean and obese diabetic groups, sug-
gesting that this insulin-independent (or AMPK-dependent) 
pathway is intact in insulin-resistant muscle tissue.30 The muscle 
protein content of AMPKA1, A2, and G3 is similar in type 2 
diabetics when compared with healthy controls.22 In addition, 
no difference was found in basal phosphorylated AMPK activity 
when the same comparison was made between insulin-resistant 
and lean muscle tissue.22 Furthermore, the basal activity of 
AMPKA1, A2, and Thr172 AMPK-A phosphorylation are all 
normal in type 2 diabetes.35,36 In support of this, normal AMPK 
activity was found despite decreased insulin-stimulated glucose 
transport when measured during euglycemic-hyperinsulinemic 
clamp in the same population.36
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2014:7submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
58
Mackenzie and Elliott
The data reported by Højlund et al,36 along with the finding 
that type 2 diabetics have normal AMPK activation during 
exercise35 while showing metformin-induced increases in 
AMPK phosphorylation,34 suggest again that AMPK function 
is intact in type 2 diabetes. The conclusion drawn from the 
work of both Musi et al34 and Højlund et al36 is that normal 
AMPK activity and reduced insulin sensitivity are metabolic 
aspects of insulin resistance, indirectly supporting the notion 
that two separate pathways operate to facilitate glucose 
transport. Further, Højlund et al36 also demonstrated that 
AMPK activity under basal conditions in human skeletal 
muscle is not regulated by normal physiological concentra-
tions of insulin. These findings taken together may suggest 
that future therapeutic targets should focus not on AMPK 
specifically, but also on prominent proteins associated with 
the insulin-signaling pathway for the treatment of insulin 
resistance. However, the targeting of AMPK for insulin resis-
tance cannot be completely disregarded, with McBride et al37 
proposing a novel role for the AMPKB subunit in glycogen 
sensing and synthesis. Further, AMPKA2 knockout mice show 
whole body insulin resistance, suggesting that AMPK may 
play a role in modulating insulin sensitivity.38 Insulin sensitiv-
ity is not altered in a dominant-negative mutant AMPK rodent 
model (Tg-KD-AMPKA2),39 although it is more susceptible 
to high-fat diet-induced insulin resistance,40 suggesting that 
AMPK is not an important mediator of insulin sensitivity 
in skeletal muscle.41 The potential role of AMPK in insulin-
stimulated glucose transport may be complicated by the recent 
findings from Sakamoto’s laboratory.42 5-aminoimidazole-4-
carboxamide ribonucleoside-induced activation of AMPK in 
knockin mice expressing a glucose-6-phosphate-insensitive 
glycogen synthase mutant demonstrates elevated glycogen 
accumulation through allosteric activation of glycogen syn-
thase, caused by elevated glucose uptake and intracellular 
glucose-6-phosphate levels. This evidence suggests that 
AMPK may be able to promote glycogen synthesis in skel-
etal muscle independent of the traditional insulin-signaling 
nexus.42 More work is clearly needed to identify how, or even 
if, AMPK affects insulin-induced glucose uptake, given that 
a direct mechanism via which AMPK is activated by insulin 
is yet to be determined.
AMPK is clearly a major target for the treatment of type 2 
diabetes. However, AMPK activation is known to be largely 
normal in this population22,43 and provides a rationale for the 
prescription of exercise in the treatment of type 2 diabetes. 
Although AMPK activation produces a number of desir-
able effects in metabolically responsive tissue, it seems to 
bypass the problem, at least in skeletal muscle. It therefore 
seems logical to focus future research on the activation/
inhibition of signaling mechanisms known to be defective in 
insulin-resistant tissue in the pursuit of future pharmaceuti-
cal treatment.
Akt/PKB isoforms
Akt, also known as PKB, is a serine/threonine-specific 
protein kinase that plays a key role in multiple cellular 
processes, including cell growth, survival, proliferation, 
and metabolism.44 Three homologous isoforms have been 
identified, ie, Akt1/PKBA, Akt2/PKBB, and Akt3/PKBG.45 
Research conducted over the past decade has identified dis-
tinct roles for each isoform, with Akt1/PKBA linked to cell 
survival, Akt2/PKBB with cell-substrate metabolism,46 and 
Akt3/PKBG with brain development.47
Akt1/PKBA is known to inhibit apoptosis via activa-
tion of NF-KB and regulation of IKB kinase, resulting in 
upregulation of prosurvival genes.48 The same isoform is 
also implicated in stimulating skeletal muscle hypertro-
phy by promoting protein synthesis and inhibiting protein 
degradation pathways, providing evidence for its roles in 
muscle homeostasis.49
Hyperglycemia and reduced glucose transport in 
muscle is present in knockout Akt2/PKBB mice,50 but is 
not apparent with deletion of the Akt1/PKBA and Akt3/
PKBG isoforms. Involvement of the Akt3/PKBG isoform 
in brain development comes from evidence examining 
Akt3 knockout mice, which shows reduced cerebral cell 
numbers and seemingly increased protein degradation and 
reduced synthesis. Further, the same Akt3/PKBG knock-
out mice show diminished mTOR (mammalian target of 
rapamycin) signaling,51 highlighting its role in cell death 
and growth inhibition.
Akt/PKB activation
PI3 kinase, following upstream stimulation by the insulin 
receptor substrate, causes recruitment of phosphatidylinositol 
(4,5)-bisphosphate (PIP2) and production of the second lipid 
messenger, phosphatidylinositol 3,4,5-trisphosphate (PIP3). 
PIP3 then binds to the pleckstrin homology domain of Akt/
PKB, allowing for its translocation and binding to the cell 
membrane. Following this membrane translocation, Akt/PKB 
can then be phosphorylated and activated52 by two further 
kinases, PDK1 and mTOR complex 2, within the T-loop 
of the catalytic domain (Thr308) and the carboxyl terminal 
hydrophobic domain (Ser473), respectively, resulting in phos-
phorylation of many downstream targets involved in cellular 
growth and metabolism.44
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Akt/PKB and insulin signaling
It is clear that Akt signaling plays a central role in insulin-
stimulated glucose uptake in both muscle and adipose tissue 
while inhibiting glucose release from hepatocytes.5 The effect 
of insulin on glucose uptake in peripheral tissue via Akt/
PKB is through its ability to translocate GLUTs to the cell 
membrane, thereby facilitating glucose uptake. Binding of 
insulin to its cell surface protein receptors causes subsequent 
tyrosine phosphorylation, resulting in phosphorylation of 
insulin receptor substrates on specific tyrosine residues and 
activation and recruitment of PI3 kinase and its downstream 
target Akt/PKB.52 The Akt substrate of 160 kDa (AS160), 
also known as TBC1D4, is an established candidate in Akt/
PKB-induced GLUT-4 translocation in skeletal muscle. 
AS160 functionally maintains Rab-GTPase(s) in an inactive 
form via guanosine-50-diphosphate-loading, thereby retain-
ing GLUT-4 within GLUT storage vesicles.14 Upon activa-
tion, Akt/PKB phosphorylates AS160, leading to a reduction 
in Rab-GAP activity, promoting GLUT-4 translocation and 
glucose uptake.14,53,54 Thus, any defects in the PI3 kinase/
Akt/AS160 transduction pathway would ultimately reduce 
glucose uptake in skeletal muscle. Similarly, hepatic deletion 
of the Akt1 and Akt2 isoform causes glucose intolerance, 
insulin resistance, and a defective insulin transcriptional 
response to feeding in hepatocytes.55
Akt/PKB and insulin resistance
Evidence from both human and animal work links insulin 
resistance with defects to both upstream and downstream 
targets of Akt/PKB in the form of dephosphorylation of 
protein side chains on insulin receptor substrates as well as 
complete loss of insulin receptor substrates from the cell sur-
face membrane,56 reduced PI3 kinase activity57 and impaired 
phosphorylation of the Akt/PKB substrate, AS160, in type 2 
diabetic skeletal muscle.58 In addition, knockdown or deple-
tion of the Akt2/PKBB isoform in mice causes insulin resis-
tance and diabetic-like symptoms, with Akt2/PKBB knockout 
rodents also demonstrating hepatic insulin resistance.59 This 
work has been extended to humans, with the finding that a 
mutation in the gene encoding Akt2/PKBB results in severe 
insulin resistance,60 establishing Akt2/PKBB as a key protein 
in the maintenance of euglycemia, given that defects in this 
important mediator would presumably result in reduced 
AS160-induced GLUT translocation.
In substituting the AS160-Thr649 phosphorylation/14-
3-3 binding residue with a nonphosphorylatable alanine, 
Chen et al were able to show that insulin-stimulated AS160 
binding to 14-3-4 is completely abolished.11 The same work 
also showed that insulin-stimulated glucose uptake and 
cell surface GLUT-4 content were reduced in this mutated 
knockin model.11 These results demonstrate the key role 
played by Akt/PKB and its downstream targets in insulin 
sensitivity and normal glucose tolerance, and may therefore 
represent an argument for its targeting as an intervention in 
the treatment of insulin resistance.
Inositol pyrophosphate  
and Akt/PKB signaling: targeting 
peripheral insulin resistance
Research in the field highlights Akt/PKB as a major signal-
ing intermediate in insulin-stimulated glucose transport in 
type 2 diabetes characterized by reduced insulin signal-
ing of Akt/PKB.45,58 Akt/PKB is known to upregulate S6 
kinase 1 (S6K1) via activation of mTOR complex 1, leading 
to phosphorylation of the serine residues on insulin receptor 
substrate-1 and resulting in Akt/PKB inhibition and a reduc-
tion in insulin-stimulated glucose uptake.61 PDK1-mediated 
phosphorylation of Akt at Thr308 is dramatically increased by 
binding of PIP3 to the pleckstrin homology domain on Akt.62 
Recent work from Chakraborty et al33 suggests a separate and 
seemingly novel feedback mechanism in the regulation of 
insulin signaling, whereby specific inositol pyrophosphates 
can also have an inhibitory effect on insulin stimulation of 
Akt/PKB by competing with PIP3 at the pleckstrin homol-
ogy domain.
Diphosphoinositol polyphosphates, also known as inosi-
tol pyrophosphates, are a family of water-soluble inositol 
phosphates.63 The most notable of these is diphosphoinositol 
pentakisphosphate (IP7),64 which has been implicated in insu-
lin secretion65 and peripheral insulin signaling (Figure 2).45 
Inositol pyrophosphates were first discovered in 1993 and 
have received a great deal of attention since due to their 
“high energy” pyrophosphate bond, which can be synthe-
sized by a family of three inositol hexakisphosphate (IP6) 
kinases (IP6Ks).66 The inositol hexakisphosphate kinase-1 
(IP6K1) isoform produces a pyrophosphate group at the 
position of IP6 to generate a further inositol pyrophosphate, 
IP7. Production of IP7 results in its binding to the pleckstrin 
homology domain of Akt/PKB, preventing its translocation to 
the cell membrane and reducing its subsequent phosphoryla-
tion by PDK1. The evidence for this comes from the finding 
that IP7 fails to prevent PDK1 Thr308 phosphorylation of Akt/
PKB lacking a pleckstrin homology domain.33 The conse-
quence of this is a reduction in insulin (Akt/PKB)-stimulated 
glucose uptake in muscle and adipose tissue (Figure 2), 
with a potential increase in accumulation of hepatic fat.33 
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Unpublished data from the authors’ laboratory shows that 
IP6K1 is detectable in human skeletal muscle and corre-
lates with one-compartment measures of insulin sensitivity 
(SI) in glucose-intolerant individuals. It is well known that 
calorie restriction in humans improves insulin sensitivity,67 
while starvation reduces IP7 formation in wild-type embry-
onic fibroblasts, again highlighting a potential mechanism 
whereby IP7 may play a role in insulin resistance.33
Does inhibition of IP7 formation 
restore normal Akt? Implications 
for obesity and insulin resistance
It seems that depletion or chemical inhibition of IP6K1 
may improve peripheral insulin action and hepatic  function. 
 Specific IP6K1 inhibitors have been shown, at least in cell 
culture, to reduce the conversion of IP6 to IP7, and so 
increase PIP3 binding to the pleckstrin homology domain of 
Akt/PKB.33,68 Padmanabhan et al68 showed that the selective 
inhibitor, N2-(m-(trifluoromethyl)benzyl) N6-(p-nitrobenzyl)
purine (TNP), reduces IP6K1 activity in a dose-dependent 
manner in vitro while reducing IP7 synthesis in vivo, 
providing the potential for decreased IP7-Akt/PKB interac-
tion and an increase in Akt/PKB membrane translocation. At 
least in the HeLa cell line, IP7 formation is returned to near 
baseline concentrations 2 hours post removal of TNP, sug-
gesting that the action of TNP on IP6K1 activity is both rapid 
and reversible.68 Using IP6K1 knockout hepatocytes,33 a 60% 
reduction in IP7 and elevations in Akt/PKB and GSK3B are 
seen in response to insulin stimulation. Similarly, these same 
hepatocytes show enhanced age-dependent phosphorylation 
of Akt at Thr308,33 suggesting a role for IP7 in age-related 
insulin resistance, with either depletion or knockout resulting 
in improved glucose tolerance by a presumable decrease in 
hepatic glucose production. The work on IP6K1 knockout 
and improved hepatic insulin resistance is a novel research 
topic with very little current published work, so provides an 
exciting avenue for future research.
This finding has been extended in IP6K1 knockout 
mouse models which have elevated Akt/PKB activity in 
response to insulin stimulation, accompanied by increased 
IRS-1 
PIP3PIP2
PI3-K PDK1
GSV
GLUT-4
IP6 IP7
IP7
IP6k1
Insulin
Rab-GTP
Rab-GAP
Activity
Rab-GDP
Akt 
Akt 
AS160 
PIP3 P
Figure 2 Inositol phosphates and Akt/PKB inhibition, a potential Akt/PKB feedback mechanism.
Note: Adapted from Cell, 143(6), Manning BD, Insulin signaling: inositol phosphates get into the Akt, 861–863. Copyright © 2010, with permission from Elsevier. 
Abbreviations: IRS, insulin receptor substrate; PI3-K, class IA phosphatidylinositol 3-kinase; PIP2, phosphatidylinositol (4,5)-bisphosphate; PIP3, phosphatidylinositol 
3,4,5-trisphosphate; PDK1, phosphoinositide-dependent protein kinase-1; Akt, serine/threonine protein kinase; AS160, 160 kDa Akt substrate; IP6K1, inositol hexakisphosphate 
kinase 1; IP6, inositol hexakisphosphate; IP7, diphosphoinositol pentakisphosphate; GLUT-4, glucose transporter 4; GSV, GLUT-4 storage vesicle; Rab-GAP, Rab-GTPase-
activating protein; Rab-GDP, guanosine-50-diphosphate-loaded Rab; Rab-GTP, guanosine-50-triphosphate-loaded Rab; P, phosphorylated site.
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glucose transport rates in skeletal muscle.33 IP6K1 mice also 
display diminished circulating insulin levels, suggesting 
increased insulin sensitivity or efficiency.69 These data are of 
note because IP6K1 knockout mice have a two-fold increase 
in insulin sensitivity when compared with their wild-type 
counterparts, and phosphorylated Akt/PKB at sites Thr308 and 
Ser473 were both increased while phosphorylated GSK3B was 
reduced in skeletal muscle.33 This is an important discovery 
because phosphorylated GSK3B Ser9 renders glycogen syn-
thesis active, resulting in the potential for increased glucose 
uptake and glycogenesis. These data were accompanied by 
a significant elevation in muscle glycogen content in IP6K1 
knockout models versus wild-type mice,33 with low muscle 
glycogen content being an inherent metabolic characteristic 
of type 2 diabetes.70 These data are important because they 
suggest that IP6K1 deletion may result in insulin hypersen-
sitivity, a known physiological consequence of elevated Akt/
PKB activity.71 Further, a reduction in IP7 by 10 MM TNP 
increased phosphorylation of Akt/PKB at Thr308 without 
affecting phosphorylation of Ser473.33 This latter finding is 
of clinical significance given that it is not likely that future 
pharmaceutical intervention acting via IP7 inhibition will 
negatively affect muscle growth and development through 
inhibition of mTOR signaling.
Interestingly, IP6K1 knockout mice also exhibit a lean 
phenotype,72 presumably as a result of increased fatty acid 
metabolism via B oxidation45 and reduced adipogenesis.73 Akt 
has been referred to as lipogenic, with double knockout of the 
Akt1 and Akt2 isoforms displaying reduced fat mass.74 Thus, 
it seems that IP7 formation, as synthesized by IP6K1 in mice, 
is implicated in obesity and insulin resistance via inhibition 
of Akt and increased GSK3B activity.33 Indeed, increased Akt 
activity and resistance to obesity are defined characteristics 
in genetic models of insulin hypersensitivity (ie, protein 
phosphatase 1B, S6K1, and JNK mutants).33,75
IPK61 inhibition and ^-cell function
Decreased B-cell function is critical to the development of 
overt type 2 diabetes.1 IP6K1 knockout mice were found to 
have lower fasting serum insulin when compared with their 
wild-type counterparts, which the authors suggested repre-
sents a loss of B-cell function.69 Depletion of IP6K1 seems 
to inhibit insulin exocytosis in B-cells,69 while maintenance 
of IP7 levels in the same cell type may enhance insulin 
secretion.76 Indeed, IP6K1 knockout rodents demonstrate a 
65%–70% reduction in circulating insulin concentrations,69 
suggesting that mice lacking IP6K1 in their pancreatic B-cells 
have reduced insulin release. However, the mutant model 
used by Bhandari et al69 also showed signs of improved 
insulin-stimulated glucose uptake. The reduction in circulat-
ing insulin levels may therefore be a product of the hyperbolic 
relationship that exists between insulin sensitivity and insulin 
secretion,77 ie, a lower insulin requirement due to a more 
efficient rate of glucose disposal. Further, IP6K1 knockout 
mice with low physiological insulin concentrations do not 
demonstrate diabetic characteristics, with normal fasting 
glucose and glycosylated hemoglobin levels, and show 
reduced body weight over a 10-week period69 and resistance 
to obesity.33 These findings are particularly exciting in light 
of the positive effect that inhibition of IP6K1 might have on 
the sensitivity of peripheral tissue to insulin via increased 
Akt/PKB activity. Inhibition of IP6K1 in B-cells requires 
more research because incubation of pancreatic Min6 cells 
with TNP results in direct inhibition of insulin release,68 and 
more importantly, this reduction in insulin release is not a 
product of increased peripheral insulin action.
Targeting isoforms: ^-cell function, 
cancer, and cell growth
The work of Bhandari et al69 in a mouse model is clearly excit-
ing, given that these authors assessed the effects of targeted 
depletion of the coding sequence of IP6K1 exon 6 on glucose 
control and insulin secretion. However, the IP6K1 mutant 
mice used in this study69 were smaller than their wild-type 
counterparts despite the same food intake, suggesting a nega-
tive consequence for protein synthesis and cell growth. This 
is surprising, given that a reduction in IP7 using the IP6K1 
inhibitor TNP does not affect phosphorylation of Akt/PKB 
at Ser473.33 The work of Bhandari et al69 may be countered by 
the knowledge that IP6K1 depletion may increase muscle pro-
tein synthesis while reducing fat accumulation,33 decreasing 
adipogenesis via GSK3B,78 and increasing Akt/PKB-induced 
fat oxidation.79 These results offer indirect evidence that 
reduced animal size69 may be due to increased fat loss rather 
than muscle atrophy, particularly given that increased p-Akt/
PKB at Ser473, as seen in IP6K1 knockout mice,33 may increase 
protein synthesis via mTOR activation.
Hyperactivity of Akt/PKB is a hallmark of most human 
forms of cancer, given that it modulates cell proliferation, 
growth, survival, and transit metabolism. In addition, overex-
pression of Akt/PKB is noted in various cancers and is pos-
sibly related to specific Akt/PKB isoforms.44 Indeed, Akt1/
PKBA is linked to breast cancer,80 Akt2/PKBB is reported 
in pancreatic cancer,33 and Akt3/PKBG mutations are associ-
ated with human melanoma.81 A detailed description of Akt/
PKB and its link to cancer is beyond the scope of this paper, 
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but this area has been comprehensively reviewed by others.44 
However, it is clear that blanket inhibition of IP6K1, with 
resulting hyperactivity of Akt/PKB in all cell types and/or in 
the whole body, cannot be advised at this stage.
Concluding remarks
Activation of AMPK has a clear beneficial effect in meta-
bolically responsive tissue in type 2 diabetics. We suggest 
that future research and potential therapies, in parallel with 
continued research into the role of AMPK in glucose control, 
should be directed towards mechanisms known to be involved 
in insulin resistance. Recent published work provides excit-
ing and novel data that may lead to a pharmaceutical agent 
capable of promoting insulin-stimulated glucose transport in 
insulin-resistant tissue via inhibition of IP6K1. Although early 
in development, use of IP6K1 inhibitors provides an inter-
esting area of research in the fight against insulin resistance 
and type 2 diabetes. Due to the varied response of Akt/PKB 
in different tissue types and the resulting individual and/or 
combined effects this kinase may have on whole body metabo-
lism, cell growth, and human cancers, blanket inhibition of 
IP6K1 and reduced production of IP7 is not recommended at 
this point. Indeed, while AMPK activity promotes growth of 
prostate cancer cells,82 use of metformin in vivo reduces the 
occurrence of pancreatic and hepatic malignancies.83 Further, 
it is important to point out that even AMPK, the current target 
protein, which is induced by metformin, is implicated in some 
cancers,82 but use of metformin is inversely correlated with 
other types of cancer in a dose-dependent manner.83
The introduction of Akt1/PKBA, Akt2/PKBB, and Akt3/
PKBG knockout rodents has suggested different physiologi-
cal functions for specific isoforms, but there is now some 
evidence pointing towards compensatory effects in a given 
isoform when another is knocked out. In terms of insulin 
resistance, it appears that future work should focus on 
pharmaceutical inhibition of IP6K1 in established animal 
models of diabetes (for example, Ob/Ob) before human trials 
can be considered. Likewise, the roles of IP6K1 depletion 
in pancreatic B-cells and in insulin production and release, 
warrant further investigation.
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